2-Amino-5-(1-methyl-5-imidazolyl)-1,3,4-thiadiazole | 1377068-92-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Amino-5-(1-methyl-5-imidazolyl)-1,3,4-thiadiazole
• 英文别名: 5-(3-methylimidazol-4-yl)-1,3,4-thiadiazol-2-amine
• CAS: 1377068-92-2
• 化学式: C₆H₇N₅S
• 分子量: 181.221
• InChiKey: DGWVBDDFDGQIAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-Amino-5-(1-methyl-5-imidazolyl)-1,3,4-thiadiazole 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三氟乙酸 作用下， 生成
  参考文献：
  名称：

  Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes

  摘要：

  GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.015
• 作为产物：
  描述：

  1-甲基-1H-咪唑-5-羰酰氯 在 吡啶 作用下， 生成 2-Amino-5-(1-methyl-5-imidazolyl)-1,3,4-thiadiazole
  参考文献：
  名称：

  Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes

  摘要：

  GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.015

文献信息

• Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes
  作者：Xiaohui Du、Yong-Jae Kim、SuJen Lai、Xi Chen、Mike Lizarzaburu、Simon Turcotte、Zice Fu、Qingxiang Liu、Ying Zhang、Alykhan Motani、Kozo Oda、Ryo Okuyama、Futoshi Nara、Michiko Murakoshi、Angela Fu、Jeff D. Reagan、Peter Fan、Yumei Xiong、Wang Shen、Leping Li、Jonathan Houze、Julio C. Medina

  DOI：10.1016/j.bmcl.2012.08.015

  日期：2012.10

  GPR142 is a novel GPCR that is predominantly expressed in pancreatic beta-cells. GPR142 agonists potentiate glucose-dependent insulin secretion, and therefore can reduce the risk of hypoglycemia. Optimization of our lead pyridinone-phenylalanine series led to a proof-of-concept compound 22, which showed in vivo efficacy in mice with dose-dependent increase in insulin secretion and a decrease in glucose levels. (C) 2012 Elsevier Ltd. All rights reserved.